Fic Capital Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,700 shares of the company’s stock after selling 3,130 shares during the period. Eli Lilly and makes up 2.0% of Fic Capital Inc.’s portfolio, making the stock its 11th biggest position. Fic Capital Inc.’s holdings in Eli Lilly and were worth $4,601,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Heritage Trust Co bought a new position in shares of Eli Lilly and during the 1st quarter valued at about $135,000. Penserra Capital Management LLC lifted its holdings in shares of Eli Lilly and by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after purchasing an additional 176 shares in the last quarter. Crestwood Advisors Group LLC bought a new position in shares of Eli Lilly and during the 1st quarter valued at about $179,000. Sandy Spring Bank lifted its holdings in shares of Eli Lilly and by 51.8% during the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after purchasing an additional 750 shares in the last quarter. Finally, Coldstream Capital Management Inc. bought a new position in shares of Eli Lilly and during the 1st quarter valued at about $200,000. Institutional investors and hedge funds own 75.77% of the company’s stock.

In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders sold 849,733 shares of company stock valued at $70,436,087 over the last three months. Company insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) traded down 1.49% on Monday, reaching $80.08. The company’s stock had a trading volume of 4,345,104 shares. The stock has a market cap of $84.48 billion, a P/E ratio of 34.65 and a beta of 0.34. The firm’s 50 day moving average is $81.40 and its 200-day moving average is $82.00. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the business posted $0.86 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.60%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.

Several equities research analysts have commented on LLY shares. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research note on Thursday. Jefferies Group LLC restated a “buy” rating and issued a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. BidaskClub cut Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Leerink Swann restated a “hold” rating on shares of Eli Lilly and in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $88.07.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/04/eli-lilly-and-company-lly-stake-decreased-by-fic-capital-inc.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.